309 related articles for article (PubMed ID: 32623818)
41. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
[TBL] [Abstract][Full Text] [Related]
42. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
[TBL] [Abstract][Full Text] [Related]
43. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach.
Bortolani S; Stura G; Ventilii G; Vercelli L; Rolle E; Ricci F; Bergui M; Mongini T
Neuromuscul Disord; 2019 Oct; 29(10):742-746. PubMed ID: 31604650
[TBL] [Abstract][Full Text] [Related]
44. Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy.
Carson VJ; Young M; Brigatti KW; Robinson DL; Reed RM; Sohn J; Petrillo M; Farwell W; Miller F; Strauss KA
Muscle Nerve; 2022 Jan; 65(1):51-59. PubMed ID: 34606118
[TBL] [Abstract][Full Text] [Related]
45. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
[TBL] [Abstract][Full Text] [Related]
46. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
47. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
[TBL] [Abstract][Full Text] [Related]
48. Anesthetic management of pediatric patients with Niemann-Pick disease type C for intrathecal 2-hydroxypropyl-β-cyclodextrin injection.
Ulloa ML; Froyshteter AB; Kret LN; Chang DP; Sarah GE; McCarthy RJ; Barnes SD; Berry-Kravis EM
Paediatr Anaesth; 2020 Jul; 30(7):766-772. PubMed ID: 32349180
[TBL] [Abstract][Full Text] [Related]
49. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
[No Abstract] [Full Text] [Related]
50. Nusinersen treatment of older children and adults with spinal muscular atrophy.
Konersman CG; Ewing E; Yaszay B; Naheedy J; Murphy S; Skalsky A
Neuromuscul Disord; 2021 Mar; 31(3):183-193. PubMed ID: 33608138
[TBL] [Abstract][Full Text] [Related]
51. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
52. Impact of Spinal Surgery on Intrathecal Nusinersen Injections in Pediatric Spinal Muscular Atrophy.
Aksoy T; Ramazanov R; Öz Yildiz S; Demirkiran G; Haliloğlu G; Yazici M
J Pediatr Orthop; 2024 Jun; ():. PubMed ID: 38888134
[TBL] [Abstract][Full Text] [Related]
53. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy.
Powell JC; Meiling JB; Cartwright MS
Muscle Nerve; 2024 Feb; 69(2):179-184. PubMed ID: 38040488
[TBL] [Abstract][Full Text] [Related]
54. Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report.
Xu B; Wei C; Hu X; Li W; Huang Z; Que C; Qiu J; Li C; Xiong H
Front Neurol; 2022; 13():869230. PubMed ID: 35547367
[TBL] [Abstract][Full Text] [Related]
55. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
[TBL] [Abstract][Full Text] [Related]
56. Ultrasound-guided transforaminal approach for nusinersen delivery in adult spinal muscle atrophy patients with challenging access.
Snoj Ž; Salapura V
Muscle Nerve; 2022 May; 65(5):585-589. PubMed ID: 35147227
[TBL] [Abstract][Full Text] [Related]
57. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3.
Hiebeler M; Abicht A; Reilich P; Walter MC
J Neuromuscul Dis; 2021; 8(4):537-542. PubMed ID: 33682724
[TBL] [Abstract][Full Text] [Related]
58. Posterior Spinal Correction and Fusion Surgery in Patients with Spinal Muscular Atrophy-Associated Scoliosis for Whom Treatment with Nusinersen Was Planned.
Machida S; Miyagi M; Saito W; Matsui A; Imura T; Inoue G; Nakazawa T; Shirasawa E; Ikeda S; Kawakubo A; Kuroda A; Yokozeki Y; Mimura Y; Uchida K; Akazawa T; Takaso M
Spine Surg Relat Res; 2021; 5(2):109-113. PubMed ID: 33842719
[TBL] [Abstract][Full Text] [Related]
59. A Systematic Review of Procedural Complications from Transforaminal Lumbar Puncture for Intrathecal Nusinersen Administration in Patients with Spinal Muscular Atrophy.
Grayev A; Schoepp M; Kuner A
AJNR Am J Neuroradiol; 2021 May; 42(5):980-985. PubMed ID: 33632735
[TBL] [Abstract][Full Text] [Related]
60. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
Li Q
Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
